

Abteilung "Klin. Pharmakologie"

Journalbeiträge

1. Conradi LC, Bleckmann A, Schirmer M, Sprenger T, Jo P, Homayounfar K, Wolff HA, Rothe H, Middel P, Becker H, Ghadimi MB, Beissbarth T, Liersch T (2011) Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. *ANN SURG ONCOL*, 18: 2442-52.
2. Hua TD, Vormfelde SV, Abed MA, Schneider-Rudt H, Sobotta P, Friede T, Chenot JF (2011) Practice nursed-based, individual and video-assisted patient education in oral anticoagulation--protocol of a cluster-randomized controlled trial. *BMC FAM PRACT*, 12: 17.
3. Meller B, Rave-Fränk M, Breunig C, Schirmer M, Baehre M, Nadrowitz R, Liersch T, Meller J (2011) Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells. *STRAHLENTHER ONKOL*, 187: 120-126.
4. Morant R, Sehrt D, Jaehde U (2011) The 8th annual meeting of CESAR in St. Gallen--novel therapeutic concepts in hemato-oncology. *INT J CLIN PHARM TH*, 49: 58-9.
5. Parmar S, Stingl JC, Huber-Wechselberger A, Kainz A, Renner W, Langsenlehner U, Krippel P, Brockmüller J, Haschke-Becher E (2011) Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. *BREAST CANCER RES*, 13: R57.
6. Sehrt D, Meineke I, Tzvetkov M, Gültepe S, Brockmüller J (2011) Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. *PHARMACOGENOMICS*, 12: 783-95.
7. Stingl Kirchheiner JC, Brockmüller J (2011) Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs. *CLIN PHARMACOL THER*, 89: 198-209.
8. Stingl JC, Etrich T, Muche R, Wiedom M, Brockmüller J, Seeringer A, Seufferlein T (2011) Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutripvention of metachronous colon adenomas in the elderly population. *BMC CANCER*, 11: 360.
9. Tzvetkov MV, Saadatmand AR, Lötsch J, Tegeder I, Stingl JC, Brockmüller J (2011) Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. *CLIN PHARMACOL THER*, 90: 143-50.
10. Tzvetkov MV, Behrens G, O'Brien VP, Hohloch K, Brockmüller J, Benöhr P (2011) Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. *PHARMACOGENOMICS*, 12: 1417-27.
11. Wolff HA, Conradi LC, Schirmer M, Beissbarth T, Sprenger T, Rave-Fränk M, Hennies S, Hess CF, Becker H, Christiansen H, Liersch T (2011) Gender-Specific Acute Organ Toxicity during Intensified Preoperative Radiochemotherapy for Rectal Cancer. *ONCOLOGIST*, 16: 621-31.
12. Wolff HA, Rolke D, Rave-Fränk M, Schirmer M, Eicheler W, Doerfler A, Hille A, Hess CF, Matthias C, Rödel RMW, Christiansen H (2011) Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines. *RADIAT ENVIRON BIOPH*, 50: 145-54.
13. Wolff HA, Hennies S, Herrmann MKA, Rave-Fränk M, Eickelmann D, Virsik P, Jung K, Schirmer M, Ghadimi M, Hess CF, Hermann RM, Christiansen H (2011) Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer. *STRAHLENTHER ONKOL*, 187: 52-8.

Zahnmedizinische Dissertationen

1. Gültepe S, Dr. med., Auswirkungen von CYP2D6-, CYP2C9 und CYP2C19-Polymorphismen auf Pharmakokinetik und Wirkungen von Carvedilol. Dissertation Universität Göttingen 2011.

Naturwiss. u.a. nichtmed. Diss.

1. Bokelmann K, Dr. rer. nat., des 5-HT3B-Promotors der Ratte vor dem Hintergrund eines mit Chemotherapie-induziertem Erbrechen assoziierten Polymorphismus. Dissertation Universität Göttingen 2011.